Alkermes Plc share price logo

Alkermes Plc

NASDAQ: ALKS

Mid Cap

$44.28

-0.64

(-1.42%)

as on

Alkermes Plc Stock Performance

as on June 15, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $44.22
    $45.65
    downward going graph

    0.14%

    Downside

    3.09%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $25.17
    $45.76
    downward going graph

    43.17%

    Downside

    3.34%

    Upside

    downward going graph

Alkermes Plc share price movements today

Previous Close
$44.92
Open
$45.18
Volume
1.1M
Day's Low - High
$44.22 - $45.65
52 Week Low - High
$25.17 - $45.76

Alkermes Plc Historical Returns

1 Month Return
+ 18.14 %
3 Month Return
+ 59.51 %
1 Year Return
+ 48.44 %
3 Year Return
+ 38.68 %
5 Year Return
+ 79.78 %

Alkermes Plc Stock Fundamentals & Key Indicators

Check Alkermes Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.4B

EPS (TTM)

1.4329

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.67%

PE Ratio (TTM)

49.2

Industry PE ratio

21.503333333333334

PEG Ratio

1.9605

EBITDA

278.6M

Revenue (TTM)

1.6B

Profit Margin

9.77%

Return On Equity TTM

9.36%

Alkermes Plc Stock Valuation

Track how Alkermes Plc P/E has moved over time to understand its valuation trends.

Alkermes Plc in the last 5 years

  • Overview

  • Trends

Lowest (9.88x)

December 31, 2024

Industry (21.50x)

June 15, 2026

Today (49.20x)

June 15, 2026

Highest (118.46x)

March 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 49.20x

Alkermes Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alkermes Plc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Alkermes Plc image
Alkermes Plc
BUY$7.4B79.78%49.29.77%NA
United Therapeutics Corporation image
United Therapeutics Corporation
BUY$23.2B205.95%20.2140.62%NA
Viatris Inc image
Viatris Inc
HOLD$19.2B7.71%NA-2.04%2.94%
Haleon plc image
Haleon plc
BUY$40.3BNA18.6315.11%2.11%
Zoetis Inc image
Zoetis Inc
BUY$33.4B-57.14%13.0428.04%2.4899999999999998%
See all

Stock Returns calculator for Alkermes Plc Stock including INR - Dollar returns

The Alkermes Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Alkermes Plc investment value today

Current value as on today

₹1,64,444

Returns

₹64,444

(+64.44%)

Returns from Alkermes Plc Stock

₹48,441 (+48.44%)

Dollar Impact

₹16,003 (+16%)

Analyst Recommendation on Alkermes Plc Stock

Based on 19 analysts

BUY

63.16%

Buy

31.58%

Hold

5.26%

Sell

Based on 19 analysts, 63.16% of analysts recommend a 'BUY' rating for Alkermes Plc. Average target price of $46.12

Alkermes Plc Share Price Target

Get share price movements and forecasts by analysts on Alkermes Plc.

What analysts predicted

3.99%UPSIDE

Target Price

$46.12

Current Price

$44.28

Analyzed by

19 Analysts

Target

$46.12

Alkermes Plc target price $46.12, a slight upside of 3.99% compared to current price of $44.28. According to 19 analysts rating.

Indian Investors' Interest in Alkermes Plc Stock

Search interest for Alkermes Plc Stock has decreased by -15% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-15% versus previous 30 day period

Alkermes Plc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
377
350
399
378
429
306
390
394
384
392
Gross Profit
307
291
337
315
367
257
341
342
338
331
Operating Income
178
43
109
104
162
13
92
89
58
-48
EBITDA
206
60
129
123
181
32
112
108
76
-21
Interest Expense
6
5
5
6
4
-
-
-
12
20
Depreciation
18
8
6
6
6
7
7
8
3
19
Income Before Tax
182
46
116
110
169
25
104
100
60
-61
Income Tax Expense
-93
7
22
17
24
3
17
17
11
4
Net Income
112
36
91
92
146
22
87
82
49
-66
Net Profit Margin
29.88%
10.51%
22.89%
24.43%
34.07%
7.33%
22.30%
21.00%
12.83%
-16.92%

Alkermes Plc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
745
903
1,094
1,170
1,038
1,173
1,111
1,663
1,557
1,475
Gross Profit
613
748
917
990
860
976
893
1,410
1,312
1,279
Operating Income
-208
-147
-99
-175
-112
97
-6
414
420
253
EBITDA
-105
-32
-7
-103
-6
177
59
519
494
330
Interest Expense
14
12
15
13
8
11
13
23
22
12
Depreciation
-
98
103
80
81
78
36
74
28
27
Income Before Tax
-214
-143
-126
-197
-96
87
-31
421
443
291
Income Tax Expense
-5
14
12
0
14
11
2
-97
71
49
Net Income
-208
-157
-139
-196
-110
-48
-158
355
367
241
Net Profit Margin
-27.95%
-17.48%
-12.73%
-16.79%
-10.67%
-4.10%
-14.24%
21.39%
23.57%
16.37%

Alkermes Plc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
36
94
92
146
22
87
82
49
-66
Operating Cash Flow
21
146
81
190
98
150
101
170
-165
Investing Cash Flow
-39
51
-109
-13
9
-29
-6
322
-2,077
Financing Cash Flow
-17
-83
-111
-281
0
0
0
10
1,474
Change in Cash
-36
114
-138
-105
108
121
95
503
-768

Alkermes Plc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-157
-139
-196
-110
-48
-158
355
367
241
Operating Cash Flow
19
99
72
82
101
21
401
439
520
Investing Cash Flow
-18
-22
-141
-11
-66
-64
53
-111
295
Financing Cash Flow
4
-1
6
-2
29
-1
-289
-494
12
Change in Cash
4
75
-62
69
64
-45
164
-166
828

Global Institutional Holdings in Alkermes Plc

Funds
Holdings
Vanguard Capital Management, LLC
4.46%
RTW INVESTMENTS, LLC
1%
Renaissance Technologies Corp
3.7%
Bvf Inc
1.2%
Vanguard Group Inc
10.8%
See all

Alkermes Plc News & Key Events

    Insights on Alkermes Plc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 2 quarters, 384.54M → 392.91M (in $), with an average increase of 2.1% per quarter

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 1 month, ALKS stock has moved up by 19.9%

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, United Therapeutics Corporation Common Stock has given 92.5% return, outperforming this stock by 41.9%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, United Therapeutics Corporation Common Stock has given 137.6% return, outperforming this stock by 96.9%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 4 quarters, 87.09M → -66.48M (in $), with an average decrease of 93.4% per quarter

    About Alkermes Plc

    Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
    OrganisationAlkermes Plc
    HeadquartersConnaught House, Dublin, Ireland, D04 C5Y6
    IndustryDrug Manufacturers - Specialty & Generic
    CEOMr. Richard F. Pops
    E-voting on sharesClick here to vote

    Key Management of Alkermes Plc

    Name

    Title

    Mr. Christian Todd Nichols

    Senior VP & Chief Commercial Officer

    Ms. Sandra Coombs

    Senior Vice President of Corporate Affairs & Investor Relations

    Mr. Stephen Schiavo

    Senior VP & Chief Human Resources Officer

    Mr. Joshua Reed M.B.A.

    Senior VP & CFO

    Mr. David Joseph Gaffin J.D.

    Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary

    Dr. Craig C. Hopkinson M.D.

    Executive VP of Research & Development and Chief Medical Officer

    Mr. Tom Skoff

    SVP & Chief Information Officer

    Mr. Richard F. Pops

    Chairman & CEO

    Mr. Blair C. Jackson

    Executive VP, Chief Risk Officer & COO

    Mr. Samuel J. Parisi

    Interim Principal Accounting Officer & VP of Finance

    FAQs

    What is Alkermes Plc share price today?

    Alkermes Plc share price today is $44.28 as on at the close of the market. Alkermes Plc share today touched a day high of $45.65 and a low of $44.22.

    What is the 52 week high and 52 week low for Alkermes Plc share?

    Alkermes Plc share touched a 52 week high of $45.76 on and a 52 week low of $25.17 on . Alkermes Plc stock price today i.e. is closed at $44.28,which is 3.23% down from its 52 week high and 75.96% up from its 52 week low.

    What is Alkermes Plc's market capitalisation today?

    Alkermes Plc market capitalisation is $0.01T as on .

    How to invest in Alkermes Plc Stock (ALKS) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Alkermes Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alkermes Plc Shares that will get you 0.0339 shares as per Alkermes Plc share price of $44.28 per share as on June 15, 2026 at 8:45 am IST.

    What is the minimum amount required to buy Alkermes Plc Stock (ALKS) from India?

    Indian investors can start investing in Alkermes Plc (ALKS) shares with as little as ₹95.1 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹951.00 in Alkermes Plc stock (as per the Rupee-Dollar exchange rate as on ). Based on Alkermes Plc share’s latest price of $44.28 as on June 15, 2026 at 8:45 am IST, you will get 0.2258 shares of Alkermes Plc. Learn more about fractional shares .

    What are the returns that Alkermes Plc has given to Indian investors in the last 5 years?

    Alkermes Plc stock has given 79.78% share price returns and 30.85% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?